Amneal Pharmaceuticals, Inc. 4

Insider Deborah M. Autor reported the vesting/settlement of 34,819 RSUs into Amneal Pharmaceuticals Class A Common Stock and received a new award of 19,824 RSUs, with no open-market buys or sells.

Deborah M. Autor, an insider of Amneal Pharmaceuticals, Inc., reported a routine equity compensation event consisting of the vesting and settlement of 34,819 restricted stock units (RSUs) into Class A Common Stock on May 7, 2026, and a separate grant of 19,824 RSUs on May 6, 2026. The Form 4 shows an RSU-to-share conversion (coded as transaction type “M”) of 34,819 RSUs into 34,819 shares of Class A Common Stock, with post‑transaction direct ownership of 128,479 shares of Class A Common Stock and 34,819 RSUs reported as held directly afterward. The newly granted 19,824 RSUs, each representing a contingent right to receive one share of Class A Common Stock, were awarded on May 6, 2026, under the company’s compensation program and will vest according to the issuer’s standard vesting schedule tied to the annual meeting and one‑year anniversary conditions. No open‑market purchases or sales for cash consideration were reported in this filing.

Filing Facts

CIK

1723128

Ticker

AMRX

Form

4

Source Type

sec

Accession

0001628280-26-032925

Alert Tier

5